Sevelamer Dosing and Administration for Adults with Chronic Kidney Disease
Target Serum Phosphorus Levels
- The National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) recommends target serum phosphorus levels of 3.5-5.5 mg/dL in dialysis patients (CKD Stage 5) 1, 2
- For non-dialysis CKD patients (Stages 3-4), the target serum phosphorus level is 2.7-4.6 mg/dL 2
Administration and Dosing
- The American College of Physicians recommends administering sevelamer 10-15 minutes before or during meals to maximize phosphate binding 1
- Sevelamer should be taken with food to bind dietary phosphorus in the gastrointestinal tract 1
Clinical Scenarios Favoring Sevelamer
- Sevelamer is strongly preferred over calcium-based binders when serum calcium exceeds 10.2 mg/dL (hypercalcemia) 1, 2
- Sevelamer is preferred when PTH levels are suppressed below 150 pg/mL on two consecutive measurements 2
- Sevelamer is preferred when patients already receive more than 2,000 mg/day of elemental calcium from calcium-based binders 3, 4, 5
- Sevelamer is preferred when severe vascular or coronary artery calcification is present 1, 2
- Sevelamer is preferred when calcium-phosphorus product exceeds 55 mg²/dL² 2, 5
Combination Therapy
- The National Kidney Foundation recommends combining sevelamer with calcium-based binders when hyperphosphatemia persists despite monotherapy, while ensuring total elemental calcium intake does not exceed 2,000 mg/day 2
- This approach allows phosphorus control while limiting calcium load and associated vascular calcification risk 3, 4
Monitoring Parameters
- The American Heart Association recommends maintaining calcium-phosphorus product below 55 mg²/dL² 2, 5
- The American College of Physicians recommends keeping serum calcium in the normal range, preferably toward the lower end (8.4-9.5 mg/dL) 2, 5